LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OABI
OmniAb, Inc.
There isn't enough reported data to score OABI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OABI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Healthy | |
| Unavailable |
OABI's revenue and cash flow are currently healthy, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OABI PE Valuation
OABI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OABI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OABI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OABI on earnings quality, reporting a profit while its opponent remains loss making.
OABI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.34 | +$0.25 |
| Q2 2026 | -$0.36 | +$0.25 |
| Q1 2026 | -$0.46 | +$0.13 |
| Q4 2025 | -$0.57 | +$0.04 |
| Q3 2025 | -$0.59 | +$0.03 |
| Q2 2025 | -$0.61 | +$0.01 |
| Q1 2025 | -$0.59 | +$0.05 |
| Q4 2024 | -$0.61 | -$0.10 |
OABI is still losing money, but less than at its worst: $0.34 per share over the past year, against $0.64 at its worst in early 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OABI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OABI on profitability, with a higher operating margin.
OABI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | +78% |
| Q2 2026 | $13.4M | +244% |
| Q1 2026 | $14.4M | +247% |
| Q4 2025 | $8.4M | -22% |
| Q3 2025 | $2.2M | -46% |
| Q2 2025 | $3.9M | -49% |
| Q1 2025 | $4.2M | +9.3% |
| Q4 2024 | $10.8M | +124% |
OABI's revenue is recovering but still below its 2023 peak: $4M last quarter, up 78% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -410% | +400 points |
| Q2 2026 | -49% | +367 points |
| Q1 2026 | -54% | +399 points |
| Q4 2025 | -188% | -41 points |
| Q3 2025 | -810% | -336 points |
| Q2 2025 | -416% | -202 points |
| Q1 2025 | -454% | +140 points |
| Q4 2024 | -147% | +293 points |
OABI's operating margin was −410% last quarter, up 400 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
OABI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +$20.5M |
| Q2 2026 | $2.6M | +$7.9M |
| Q1 2026 | -$5.1M | +$11M |
| Q4 2025 | -$5.7M | -$1.8M |
| Q3 2025 | -$9.9M | -$3.2M |
| Q2 2025 | -$5.3M | +$7.6M |
| Q1 2025 | -$16.1M | +$1.9M |
| Q4 2024 | -$3.9M | +$5.3M |
OABI's free cash flow has turned positive after three years mostly in the red: $2M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OABI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OABI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +500K shares |
| 1 year | +22% | +23.1M shares |
| 3 years | +30% | +29.8M shares |
OABI has 129M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OABI Net Leverage
OABI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OABI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 86.4 | Overbought |
OABI's weekly RSI is 71 (overbought) and its Stochastic is 86 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OABI PE vs Healthcare Sector
OABI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OABI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.83 | 2.5% above |
| 20 week MA | $3.88 | 28% above |
| 50 week MA | $2.70 | 83% above |
| 100 week MA | $2.45 | 102% above |
| 200 week MA | $3.54 | 40% above |
OABI has climbed back above all five of its weekly moving averages, and it's now 40% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
OABI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $6.61 | $3.56 | -46% |
| 2023 | $3.56 | $6.17 | +73% |
| 2024 | $6.17 | $3.59 | -42% |
| 2025 | $3.59 | $1.93 | -46% |
| 2026 YTD | $1.93 | $4.95 | +156% |
OABI has the edge over LLY on returns for 2026, with the stronger performance.